The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Quva would like to inform you of a recall of certain lots of Quva's ready-to-administer ("RTA") Methohexital Sodium 100 mg (10 mg/mL) in Sterile Water, 10 mL Syringe Product (Product Code 70092-1310-46) (the "RTA Methohexital Syringe Product"). This action is being taken as a result of a recall initiated by Avet Pharmaceuticals, Inc. ("Avet") of its FDA-approved Methohexital Sodium for Injection USP 500 mg Multiple Dose Vial (NDC 23155-893-31). Avet's FDA-approved Methohexital product is a component used in Quva's RTA Methohexital Syringe Product. The affected lots of Quva's RTA Methohexital Syringe Product were compounded by Quva's Sugar Land, Texas facility between April 22, 2026 and May 12, 2026. The Methohexital Product includes 34 lots that were distributed by Quva to 140 hospitals between May 6, 2026, and June 2, 2026.

Patient safety is our top priority. Quva's manufacturing process for its RTA Methohexital Syringe Product incorporates thorough incoming component and post-production inspection steps, sterile filtration, and release testing. No adverse events or patient injuries have been reported in connection with the administration of the affected lots of Quva's RTA Methohexital Syringe Product.

This recall is being conducted to the hospital/provider level.

PRODUCT: Methohexital Sodium 100 mg (10 mg/mL) in Sterile Water, 10 mL Syringe

PRODUCT CODE: 70092-1310-46